The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Updates in the management of brain metastases
Open accessAbstract
The clinical management/understanding of brain metastases (BM) has changed substantially in the last 5 years, with key advances and clinical trials highlighted in this review. Several of these changes stem from improvements in systemic therapy, which have led to better systemic control and longer overall patient survival, associated with increased time at risk for developing BM. Development of systemic therapies capable of preventing BM and controlling both intracranial and extracranial disease once BM are diagnosed is paramount. The increase in use of stereotactic radiosurgery alone for many patients with multiple BM is an outgrowth of the desire to employ treatments focused on local control while minimizing cognitive effects associated with whole brain radiotherapy. Complications from BM and their treatment must be considered in comprehensive patient management, especially with greater awareness that the majority of patients do not die from their BM. Being aware of significant heterogeneity in prognosis and therapeutic options for patients with BM is crucial for appropriate management, with greater attention to developing individual patient treatment plans based on predicted outcomes; in this context, recent prognostic models of survival have been extensively revised to incorporate molecular markers unique to different primary cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · cited 1×
“In a Phase III randomized trial of the ALK inhibitor crizotinib, 35% of patients with ALK-rearranged NSCLC had BM at the time of study entry.(151) Based on pooled analysis of 2 large clinical trials of crizotinib in patients with ALK-rearranged advanced NSCLC, 20% of patients without BM at baseline and 70% of patients…”
BackgroundSelf-citationNivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Gaspar, L., Scott, C., Rotman, M., Asbell, S., Phillips, T., Wasserman, T., McKenna, W. G., & Byhardt, R. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00619-0 · Cited by 2,544
Chang, E. L., Wefel, J. S., Hess, K. R., Allen, P. K., Lang, F. F., Kornguth, D. G., Arbuckle, R. B., Swint, J. M., Shiu, A. S., Maor, M. H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70263-3 · Cited by 2,475
Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., Kenjyo, M., Oya, N., Hirota, S., Shioura, H., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2483 · Cited by 2,213
Kocher, M., Soffietti, R., Abacioglu, U., Villà, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., Kortmann, R.-D., Carrie, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1655 · Cited by 1,988
Self-citationPostoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial
Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., Markesbery, W. R., Foon, K. A., & Young, B. (1998) · JAMA · doi:10.1001/jama.280.17.1485 · Cited by 1,915
Barnholtz-Sloan, J. S., Sloan, A. E., Davis, F. G., Vigneau, F. D., Lai, P., & Sawaya, R. E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.149 · Cited by 1,843
Yamamoto, M., Serizawa, T., Shuto, T., Akabane, A., Higuchi, Y., Kawagishi, J., Yamanaka, K., Sato, Y., Jokura, H., Yomo, S., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70061-0 · Cited by 1,447 · cited 17×
“A large Japanese prospective observational study by Yamamoto et al among 1194 patients with 1–10 BM under 3 cm in diameter and KPS ≥ 70 who were treated with stereotactic radiosurgery (SRS) alone found that among the 850 patients who had died as of last follow-up, 92% died from systemic disease progression, and not fr…”
BackgroundInfluentialSperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., Sneed, P. K., Chao, S. T., Weil, R. J., Suh, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0527 · Cited by 1,425 · cited 1×
“The prognostic index that has now become the most prominent is the Graded Prognostic Assessment (GPA), which was originally developed from a database of nearly 2000 patients with newly diagnosed BM accrued to 4 RTOG protocols, and later serially refined to include patients treated across multiple institutions and to i…”
MethodSelf-citationBendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
CNS Metastases in Breast Cancer: Old Challenge, New Frontiers
Lin, N. U., Amiri-Kordestani, L., Palmieri, D., Liewehr, D. J., & Steeg, P. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0790 · Cited by 1,286
Self-citationMicroenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth
Zhang, L., Zhang, S., Yao, J., Lowery, F. J., Zhang, Q., Huang, W.-C., Li, P., Li, M., Wang, X., Zhang, C., et al. (2015) · Nature · doi:10.1038/nature15376 · Cited by 1,175
Gondi, V., Pugh, S. L., Tome, W. A., Caine, C., Corn, B., Kanner, A., Rowley, H., Kundapur, V., DeNittis, A., Greenspoon, J. N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2909 · Cited by 1,148
Self-citationIpilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Self-citationResponse assessment criteria for brain metastases: proposal from the RANO group
Lin, N. U., Lee, E. Q., Aoyama, H., Barani, I. J., Barboriak, D. P., Baumert, B. G., Bendszus, M., Brown, P. D., Camidge, D. R., Chang, S. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70057-4 · Cited by 1,088
Self-citationBrastianos, P. K., Carter, S. L., Santagata, S., Cahill, D. P., Taylor-Weiner, A., Jones, R. T., Van Allen, E. M., Lawrence, M. S., Horowitz, P. M., Cibulskis, K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0369 · Cited by 1,082
Self-citationOvercoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Brain metastases: epidemiology and pathophysiology
Gavrilovic, I. T., & Posner, J. B. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-8093-6 · Cited by 975
Brown, P. D., Pugh, S., Laack, N. N., Wefel, J. S., Khuntia, D., Meyers, C., Choucair, A., Fox, S., Suh, J. H., Roberge, D., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not114 · Cited by 958
Self-citationBorgelt, B., Gelber, R., Kramer, S., Brady, L. W., Chang, C. H., Davis, L. W., Perez, C. A., & Hendrickson, F. R. (1980) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(80)90195-9 · Cited by 953
Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70431-x · Cited by 918
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Levin, V. A., Bidaut, L., Hou, P., Kumar, A. J., Wefel, J. S., Bekele, B. N., Prabhu, S., Loghin, M., Gilbert, M. R., & Jackson, E. F. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.12.061 · Cited by 729
Lin, N. U., Claus, E., Sohl, J., Razzak, A. R., Arnaout, A., & Winer, E. P. (2008) · Cancer · doi:10.1002/cncr.23930 · Cited by 727
Self-citationGadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A. A., West, H. L., Azada, M. C., Morcos, P. N., Lee, R.-M., Garcia, L., Yu, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70362-6 · Cited by 698
Lockman, P. R., Mittapalli, R. K., Taskar, K. S., Rudraraju, V., Gril, B., Bohn, K. A., Adkins, C. E., Roberts, A., Thorsheim, H. R., Gaasch, J. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1564 · Cited by 693
Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Aisner, D. L., Gaspar, L. E., Kavanagh, B. D., Doebele, R. C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745948 · Cited by 684 · cited 1×
“In patients with ALK-rearranged NSCLC, the CNS is the first site of progression in 46% of patients treated with crizotinib.(11) Despite these remarkable subgroup findings, the only populations currently recommended by the National Comprehensive Cancer Network to undergo a screening brain MRI at diagnosis in the absenc…”
BackgroundSelf-citationConsensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
(2015) · Neuro-Oncology · doi:10.1093/neuonc/nov095 · Cited by 663
Lin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Self-citationSoffietti, R., Kocher, M., Abacioglu, U. M., Villa, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., Kortmann, R.-D., Carrie, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0639 · Cited by 636
Self-citationCosta, D. B., Shaw, A. T., Ou, S.-H. I., Solomon, B. J., Riely, G. J., Ahn, M.-J., Zhou, C., Shreeve, S. M., Selaru, P., Polli, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0539 · Cited by 599
Self-citationTsao, M. N., Rades, D., Wirth, A., Lo, S. S., Danielson, B. L., Gaspar, L. E., Sperduto, P. W., Vogelbaum, M. A., Radawski, J. D., Wang, J. Z., et al. (2012) · Practical Radiation Oncology · doi:10.1016/j.prro.2011.12.004 · Cited by 587
Self-citationOu, S.-H. I., Ahn, J. S., De Petris, L., Govindan, R., Yang, J. C.-H., Hughes, B., Lena, H., Moro-Sibilot, D., Bearz, A., Ramirez, S. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9443 · Cited by 580
Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00614-2 · Cited by 471 · cited 1×
“In Phase I studies of alectinib or ceritinib that allowed patients with CNS metastases and no prior brain radiotherapy at study entry, 3 of 4 patients with measurable CNS disease in the alectinib study and 6 of 11 patients with measurable CNS disease in the ceritinib study achieved a complete or partial CNS response.(…”
BackgroundSelf-citationLin, X., & DeAngelis, L. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9503 · Cited by 441
Sahgal, A., Aoyama, H., Kocher, M., Neupane, B., Collette, S., Tago, M., Shaw, P., Beyene, J., & Chang, E. L. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.10.024 · Cited by 420
Brain Metastases: The HER2 Paradigm
Lin, N. U., & Winer, E. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2478 · Cited by 417
Self-citationWhole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases
Tsao, M. N., Lloyd, N., Wong, R. K., Chow, E., Rakovitch, E., Laperriere, N., Xu, W., & Sahgal, A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003869.pub3 · Cited by 399
Welsh, J. W., Komaki, R., Amini, A., Munsell, M. F., Unger, W., Allen, P. K., Chang, J. Y., Wefel, J. S., McGovern, S. L., Garland, L. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1174 · Cited by 395
Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., & Lassman, A. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor121 · Cited by 349 · cited 2×
“A retrospective analysis suggested that pulsatile dosing is well tolerated and effective in patients with EGFR-mutant lung cancers with CNS metastases (parenchymal and leptomeningeal) even after progression on standard dosing erlotinib.(110) Some antitumor agents are not dependent on whether they can cross an intact o…”
BackgroundGefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial
Ceresoli, G. L., Cappuzzo, F., Gregorc, V., Bartolini, S., Crinò, L., & Villa, E. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh276 · Cited by 349
Mehta, M. P., Tsao, M. N., Whelan, T. J., Morris, D. E., Hayman, J. A., Flickinger, J. C., Mills, M., Rogers, C. L., & Souhami, L. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.05.023 · Cited by 346
Self-citationAntonadou, D., Paraskevaidis, M., Sarris, G., Coliarakis, N., Economou, I., Karageorgis, P., & Throuvalas, N. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.140 · Cited by 331
Johung, K. L., Yeh, N., Desai, N. B., Williams, T. M., Lautenschlaeger, T., Arvold, N. D., Ning, M. S., Attia, A., Lovly, C. M., Goldberg, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0138 · Cited by 328
Self-citationEpidemiology of Metastatic Brain Tumors
Fox, B. D., Cheung, V. J., Patel, A. J., Suki, D., & Rao, G. (2011) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2010.08.007 · Cited by 317
Awada, A., Colomer, R., Inoue, K., Bondarenko, I., Badwe, R. A., Demetriou, G., Lee, S.-C., Mehta, A. O., Kim, S.-B., Bachelot, T., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0237 · Cited by 305
Li, J., Bentzen, S. M., Li, J., Renschler, M., & Mehta, M. P. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.09.059 · Cited by 287
Self-citationSperduto, P. W., Wang, M., Robins, H. I., Schell, M. C., Werner-Wasik, M., Komaki, R., Souhami, L., Buyyounouski, M. K., Khuntia, D., Demas, W., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.11.042 · Cited by 274
Self-citationRapp, S. R., Case, L. D., Peiffer, A., Naughton, M. M., Chan, M. D., Stieber, V. W., Moore, D. F., Falchuk, S. C., Piephoff, J. V., Edenfield, W. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.4508 · Cited by 270
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
Kodama, T., Hasegawa, M., Takanashi, K., Sakurai, Y., Kondoh, O., & Sakamoto, H. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2578-6 · Cited by 243
Pivot, X., Manikhas, A., Żurawski, B., Chmielowska, E., Karaszewska, B., Allerton, R., Chan, S., Fabi, A., Bidoli, P., Gori, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1794 · Cited by 242 · cited 1×
“The CEREBEL study was a Phase III, randomized trial of lapatinib + capecitabine versus trastuzumab + capecitabine for prevention of CNS metastases.(126) Unfortunately, the study was closed early and was inconclusive for its primary endpoint.”
MethodBevacizumab Safety in Patients with Central Nervous System Metastases
Besse, B., Lasserre, S. F., Compton, P., Huang, J., Augustus, S., & Rohr, U.-P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2439 · Cited by 241
Wu, Y.-L., Zhou, C., Cheng, Y., Lu, S., Chen, G.-Y., Huang, C., Huang, Y.-S., Yan, H.-H., Ren, S., Liu, Y., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds529 · Cited by 234
Besse, B., Le Moulec, S., Mazières, J., Senellart, H., Barlesi, F., Chouaid, C., Dansin, E., Bérard, H., Falchero, L., Gervais, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2082 · Cited by 226
Aoyama, H., Tago, M., & Shirato, H. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1145 · Cited by 220
Clarke, J. L., Pao, W., Wu, N., Miller, V. A., & Lassman, A. B. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0128-6 · Cited by 214 · cited 1×
“Pulsatile dosing of erlotinib at 1500 mg once weekly is associated with a CSF concentration of 130 nM, sufficient to inhibit 50% growth in cancer cell lines.(109) A retrospective analysis suggested that pulsatile dosing is well tolerated and effective in patients with EGFR-mutant lung cancers with CNS metastases (pare…”
BackgroundVerger, E., Gil, M., Yaya, R., Viñolas, N., Villà, S., Pujol, T., Quintó, L., & Graus, F. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.04.061 · Cited by 211
Pestalozzi, B. C., Holmes, E., de Azambuja, E., Metzger-Filho, O., Hogge, L., Scullion, M., Láng, I., Wardley, A., Lichinitser, M., Sanchez, R. I. L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70017-2 · Cited by 210
Mitsuya, K., Nakasu, Y., Horiguchi, S., Harada, H., Nishimura, T., Bando, E., Okawa, H., Furukawa, Y., Hirai, T., & Endo, M. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0106-z · Cited by 205
Gondi, V., Paulus, R., Bruner, D. W., Meyers, C. A., Gore, E. M., Wolfson, A., Werner-Wasik, M., Sun, A. Y., Choy, H., & Movsas, B. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.02.033 · Cited by 198
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
Zhang, I., Zaorsky, N. G., Palmer, J. D., Mehra, R., & Lu, B. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00013-3 · Cited by 193
Ramakrishna, N., Temin, S., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Giordano, S. H., Gonzalez-Angulo, A. M., Kirshner, J. J., Krop, I., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0955 · Cited by 191
Self-citationAmerican Society for Radiation Oncology
(2015) · The SAGE Encyclopedia of Cancer and Society · doi:10.4135/9781483345758.n37 · Cited by 188
Central Nervous System Cancers, Version 1.2015
Nabors, L. B., Portnow, J., Ammirati, M., Baehring, J., Brem, H., Brown, P., Butowski, N., Chamberlain, M. C., Fenstermaker, R. A., Friedman, A., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0148 · Cited by 178
Self-citationHeon, S., Yeap, B. Y., Lindeman, N. I., Joshi, V. A., Butaney, M., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0357 · Cited by 176
Morikawa, A., Peereboom, D. M., Thorsheim, H. R., Samala, R., Balyan, R., Murphy, C. G., Lockman, P. R., Simmons, A., Weil, R. J., Tabar, V., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou141 · Cited by 173
Nonoguchi, N., Miyatake, S.-I., Fukumoto, M., Furuse, M., Hiramatsu, R., Kawabata, S., Kuroiwa, T., Tsuji, M., Fukumoto, M., & Ono, K. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0610-9 · Cited by 172
Freedman, R. A., Gelman, R. S., Wefel, J. S., Melisko, M. E., Hess, K. R., Connolly, R. M., Van Poznak, C. H., Niravath, P. A., Puhalla, S. L., Ibrahim, N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0343 · Cited by 171
Self-citationMehta, M. P., Paleologos, N. A., Mikkelsen, T., Robinson, P. D., Ammirati, M., Andrews, D. W., Asher, A. L., Burri, S. H., Cobbs, C., Gaspar, L. E., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0062-7 · Cited by 155
Self-citationPaik, P. K., Shen, R., Won, H. H., Rekhtman, N., Wang, L., Sima, C. S., Arora, A., Seshan, V., Ladanyi, M., Berger, M. F., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1129 · Cited by 153
A nomogram for individualized estimation of survival among patients with brain metastasis
Barnholtz‐Sloan, J. S., Yu, C., Sloan, A. E., Vengoechea, J. E., Wang, M., Dignam, J. J., Vogelbaum, M. A., Sperduto, P. W., Mehta, M. P., Machtay, M. X., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos087 · Cited by 152
Self-citationJamal‐Hanjani, M., & Spicer, J. F. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2529 · Cited by 151
Lin, N., Wefel, J. S., Lee, E. Q., Schiff, D., van den Bent, M. J., Soffietti, R., Suh, J. H., Vogelbaum, M. A., Mehta, M. P., Dancey, J. E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70308-5 · Cited by 147
Self-citationMargolin, K. A., Atkins, M. B., Thompson, J. F., Ernstoff, M. S., Weber, J. S., Flaherty, L. E., Clark, J. I., Weiss, G. R., Sosman, J. A., Smith, J. W., et al. (2002) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-002-0323-8 · Cited by 145
Self-citationParrish, K., Sarkaria, J. N., & Elmquist, W. F. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.71 · Cited by 141
Lin, N., Lee, E. Q., Aoyama, H., Barani, I. J., Baumert, B. G., Brown, P. D., Camidge, D. R., Chang, S. M., Dancey, J. E., Gaspar, L. E., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70311-5 · Cited by 136
Self-citationThe accuracy of predicting survival in individual patients with cancer: Clinical article
Kondziolka, D. S., Parry, P. V., Lunsford, L. D., Kano, H., Flíckinger, J. C., Rakfal, S. M., Arai, Y., Loeffler, J. S., Rush, S. C., Knisely, J. P. S., et al. (2013) · Journal of neurosurgery · doi:10.3171/2013.9.jns13788 · Cited by 132
Choosing Wisely: The American Society for Radiation Oncology’s Top 5 list
Hahn, C. A., Kavanagh, B. D., Bhatnagar, A. K., Jacobson, G. M., Lutz, S., Patton, C., Potters, L., & Steinberg, M. B. (2014) · Practical Radiation Oncology · doi:10.1016/j.prro.2014.06.003 · Cited by 130
Cortés, J., Dieras, V. C., Ro, J., Barrière, J., Bachelot, T., Hurvitz, S. A., Rhun, É. L., Espié, M., Kim, S., Schneeweiß, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00373-3 · Cited by 129
Grandhi, R., Kondziolka, D. S., Panczykowski, D. M., Monaco, E. A., Kano, H., Niranjan, A., Flíckinger, J. C., & Lunsford, L. D. (2012) · Journal of neurosurgery · doi:10.3171/2012.4.jns11870 · Cited by 127
Hsu, F., Carolan, H., Nichol, A., Cao, F., Nuraney, N., Lee, R., Gete, E., Wong, F., Schmuland, M., Heran, M. K. S., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.03.032 · Cited by 124
Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer
Bearz, A., Garassino, I. M. G., Tiseo, M., Caffo, O., Parra, H. J. S., Boccalon, M., Talamini, R., Santoro, A., Bartolotti, M., Murgia, V., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.06.018 · Cited by 120
Activity of T-DM1 in Her2-positive breast cancer brain metastases
Bartsch, R., Berghoff, A. S., Vogl, U. M., Rudas, M., Bergen, E. S., Dubsky, P. C., Dieckmann, K. U., Pinker, K., Bagó-Horváth, Z., Galid, A., et al. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9740-3 · Cited by 119
Ojerholm, E., Lee, J. Y. K., Thawani, J. P., Miller, D., O’Rourke, D. M., Dorsey, J. F., Geiger, G. A., Nagda, S. N., Kolker, J. D., Lustig, R. A., et al. (2014) · Journal of neurosurgery · doi:10.3171/2014.6.gks14708 · Cited by 114
Prognostic indices for brain metastases – usefulness and challenges
Nieder, C., & Mehta, M. P. (2009) · Radiation Oncology · doi:10.1186/1748-717x-4-10 · Cited by 110
Self-citationHorky, L. L., Hsiao, E., Weiss, S. E., Drappatz, J., & Gerbaudo, V. H. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0365-8 · Cited by 108
Evolving treatment options for melanoma brain metastases
Ajithkumar, T., Parkinson, C., Fife, K. M., Corrie, P. G., & Jefferies, S. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00141-2 · Cited by 104
Monaco, E. A., Faraji, A. H., Berkowitz, O., Parry, P. V., Hadelsberg, U. P., Kano, H., Niranjan, A., Kondziolka, D. S., & Lunsford, L. D. (2012) · Cancer · doi:10.1002/cncr.27504 · Cited by 103
Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke, W. C. M., Edvardsen, K., Lü, S., Reinmuth, N., Reck, M., & Inoue, A. (2015) · PubMed · Cited by 102
Guerrieri, M., Wong, K., Ryan, G. F., Millward, M. J., Quong, G., & Ball, D. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.02.019 · Cited by 100
Neuhaus, T., Ko, Y., Müller, R.-P., Grabenbauer, G. G., Hedde, J.-P., Schueller, H., Köcher, M., Stier, S., & Fietkau, R. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604835 · Cited by 99
Chun, S. G., Choe, K. S., Iyengar, P., Yordy, J. S., & Timmerman, R. D. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.22255 · Cited by 99
Radiosurgery of multiple brain metastases with single-isocenter dynamic conformal arcs (SIDCA)
Huang, Y., Chin, K., Robbins, J. R., Kim, J., Li, H., Amro, H., Chetty, I. J., Gordon, J., & Ryu, S. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.05.009 · Cited by 99
Chemotherapy of brain metastases from lung carcinoma
Ushio, Y., Arita, N., Hayakawa, T., et al. (1991) · Neurosurgery · doi:10.1097/00006123-199102000-00005 · Cited by 98
Knisely, J. P. S., Berkey, B. A., Chakravarti, A., Yung, A. W. K., Curran, W. J., Robins, H. I., Movsas, B., Brachman, D. G., Henderson, R. H., & Mehta, M. P. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.09.016 · Cited by 93
Self-citationHypofractionated stereotactic radiotherapy for the treatment of brain metastases
Kwon, A., DiBiase, S. J., Wang, B., Hughes, S., Milcarek, B. I., & Zhu, Y. (2009) · Cancer · doi:10.1002/cncr.24082 · Cited by 92
Steeg, P. S. (2012) · Nature · doi:10.1038/485s58a · Cited by 82
Takeda, M., Okamoto, I., & Nakagawa, K. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828c28e7 · Cited by 80
Lin, N., Freedman, R. A., Ramakrishna, N. R., Younger, J., Storniolo, A. M., Bellon, J. R., Come, S. E., Gelman, R. S., Harris, G. J., Henderson, M. A., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2754-0 · Cited by 64
Self-citationEvidence-Based Guidelines for the Management of Brain Metastases
Bhangoo, S. S., Linskey, M. E., & Kalkanis, S. N. (2010) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2010.09.001 · Cited by 60
Cao, K. I., Lebas, N., Gerber, S., Lévy, C., Scodan, R. L., Bourgier, C., Pierga, J., Gobillion, A., Savignoni, A., & Kirova, Y. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu488 · Cited by 57
Burch, P. A., Grossman, S. A., & Reinhard, C. S. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.15.1211 · Cited by 54
Four, S. D., Wilgenhof, S., Duerinck, J., Michotte, A., Vanbinst, A., Ridder, M. D., & Neyns, B. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.016 · Cited by 53
Updates on the management of breast cancer brain metastases.
Lim, E., & Lin, N. U. (2014) · PubMed · Cited by 47
Self-citationLocal control after fractionated stereotactic radiation therapy for brain metastases
Rajakesari, S., Arvold, N. D., Jimenez, R., Christianson, L. W., Horvath, M. C., Claus, E. B., Golby, A. J., Johnson, M. D., Dunn, I. F., Lee, E. Q., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1556-5 · Cited by 46
Self-citationCNS Metastases in Patients With Non–Small-Cell Lung Cancer and ALK Gene Rearrangement
Shi, W., & Dicker, A. P. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9682 · Cited by 35
Taking Aim at ALK Across the Blood–Brain Barrier
Camidge, D. R. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182864e7c · Cited by 28
Self-citationBrain metastasis: opportunity for drug development?
Preusser, M., Berghoff, A. S., Schadendorf, D., Lin, N., & Stupp, R. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328359320d · Cited by 22
Self-citationArvold, N. D., Pinnell, N. E., Mahadevan, A., Connelly, S., Silverman, R., Weiss, S. E., Kelly, P. J., & Alexander, B. M. (2015) · Practical Radiation Oncology · doi:10.1016/j.prro.2015.11.004 · Cited by 21
Self-citationLiu, Y., Alexander, B. M., Chen, Y., Horvath, M. C., Aizer, A. A., Claus, E. B., Dunn, I. F., Golby, A. J., Johnson, M. D., Friesen, S. A., et al. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1855-5 · Cited by 14
Self-citationLocal Therapies for Brain Metastases, Competing Risks, and Overall Survival
Arvold, N. D., & Catalano, P. J. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.12.003 · Cited by 8
Self-citationDrug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy
Stricker, T. P., & Arteaga, C. L. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1166 · Cited by 6
Lin, N., Gabrail, N. Y., Sarantopoulos, J., Schwartzberg, L. S., Kesari, S., Bates, S. E., Anders, C. K., ELIAS, A. D., Castaigne, J., Iordanova, V., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2523 · Cited by 5
Self-citationRecurrent radiation necrosis in the brain following stereotactic radiosurgery
Parker, G., Dunn, I. F., Ramkissoon, S. H., Eneman, J. D., Rabin, M. S., & Arvold, N. D. (2014) · Practical Radiation Oncology · doi:10.1016/j.prro.2014.10.006 · Cited by 4
Self-citation
Cited by
Response Assessment in Neuro-Oncology Clinical Trials
Wen, P. Y., Chang, S. M., Van den Bent, M. J., Vogelbaum, M. A., Macdonald, D. R., & Lee, E. Q. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7511 · Cited by 435
Self-citationBartsch, R., Berghoff, A. S., Furtner, J., Marhold, M., Bergen, E. S., Roider-Schur, S., Starzer, A. M., Forstner, H., Rottenmanner, B., Dieckmann, K., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01935-8 · Cited by 389
McFaline-Figueroa, J. R., & Lee, E. Q. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.12.039 · Cited by 272
Self-citationKaufmann, T. J., Smits, M., Boxerman, J., Huang, R., Barboriak, D. P., Weller, M., Chung, C., Tsien, C., Brown, P. D., Shankar, L., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa030 · Cited by 267
Self-citationChukwueke, U. N., & Wen, P. Y. (2019) · CNS Oncology · doi:10.2217/cns-2018-0007 · Cited by 256
Self-citation
Metadata
- Authors
- Arvold, N. D., Lee, E. Q., Mehta, M. P., Margolin, K., Alexander, B. M., Lin, N. U., Anders, C. K., Soffietti, R., Camidge, D. R., Vogelbaum, M. A., Dunn, I. F., & Wen, P. Y.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-07-05
- Volume
- 18
- Issue
- 8
- Pages
- 1043-1065
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2460924712
- Cited by
- 275
- References
- 119
- FWCI
- 21.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.